ArticleFrontiers in medicine2026
The FT4/FT3 ratio combined with thyroglobulin and parathyroid hormone for distinguishing benign from malignant thyroid nodules: a retrospective study based on histopathological diagnosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the diagnostic value of the FT4/FT3 ratio combined with other laboratory markers in distinguishing malignant from benign thyroid nodules. Methods: This retrospective study analyzed 359 patients with thyroid nodules (142 benign, 217 malignant) based on histopathological results. Clinical and laboratory data, including FT3, FT4, FT4/FT3 ratio, thyroglobulin (TG), parathyroid hormone (PTH), and TSH, were collected. Statistical analyses included ROC curves and multivariate logistic regression. Results: Malignant nodules showed higher FT4/FT3 ratios, TG, PTH, and TSH levels ( Conclusion: The FT4/FT3 ratio, combined with TG and PTH levels, enhances the differentiation of malignant thyroid nodules, offering a reliable diagnostic tool.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.